Khan Mushfiquddin, Dhammu Tajinder S, Singh Inderjit, Singh Avtar K
Department of Pediatrics, 508 Children's Research Institute, Medical University of South Carolina, 173 Ashley Ave, Charleston, SC, 29425, USA.
Ralph H Johnson VA Medical Center, Charleston, SC, USA.
BMC Neurosci. 2018 Aug 13;19(1):50. doi: 10.1186/s12868-018-0450-z.
Spinal cord injury (SCI) is one of the leading causes of disability and chronic pain. In SCI-induced pathology, homeostasis of the nitric oxide (NO) metabolome is lost. Major NO metabolites such as S-nitrosoglutathione (GSNO) and peroxynitrite are reported to play pivotal roles in regulating the activities of key cysteine proteases, calpains. While peroxynitrite (a metabolite of NO and superoxide) up regulates the activities of calpains leading to neurodegeneration, GSNO (a metabolite of NO and glutathione) down regulates the activities of calpains leading to neuroprotection. In this study, effect of GSNO on locomotor function and pain threshold and their relationship with the levels of peroxynitrite and the activity of calpain in the injured spinal cord were investigated using a 2-week rat model of contusion SCI.
SCI animals were initially treated with GSNO at 2 h after the injury followed by a once daily dose of GSNO for 14 days. Locomotor function was evaluated by "Basso Beattie and Bresnahan (BBB) locomotor rating scale" and pain by mechanical allodynia. Peroxynitrite level, as expression of 3-nitrotyrosine (3-NT), calpain activity, as the degradation products of calpain substrate alpha II spectrin, and nNOS activity, as the expression phospho nNOS, were measured by western blot analysis. Treatment with GSNO improved locomotor function and mitigated pain. The treatment also reduced the levels of peroxynitrite (3-NT) and decreased activity of calpains. Reduced levels of peroxynitrite resulted from the GSNO-mediated inhibition of aberrant activity of neuronal nitric oxide synthase (nNOS).
The data indicates that higher levels of 3-NT and aberrant activities of nNOS and calpains correlated with SCI pathology and functional deficits. Treatment with GSNO improved locomotor function and mitigated mechanical allodynia acutely post-injury. Because GSNO shows potential to ameliorate experimental SCI, we discuss implications for GSNO therapy in clinical SCI research.
脊髓损伤(SCI)是导致残疾和慢性疼痛的主要原因之一。在SCI引发的病理过程中,一氧化氮(NO)代谢组的稳态丧失。据报道,主要的NO代谢产物如S-亚硝基谷胱甘肽(GSNO)和过氧亚硝酸盐在调节关键半胱氨酸蛋白酶(钙蛋白酶)的活性中起关键作用。当过氧亚硝酸盐(NO和超氧化物的代谢产物)上调钙蛋白酶的活性导致神经变性时,GSNO(NO和谷胱甘肽的代谢产物)下调钙蛋白酶的活性导致神经保护。在本研究中,使用2周的大鼠脊髓挫伤模型研究了GSNO对运动功能和疼痛阈值的影响及其与损伤脊髓中过氧亚硝酸盐水平和钙蛋白酶活性的关系。
SCI动物在损伤后2小时先用GSNO治疗,然后每天一次给予GSNO,持续14天。通过“Basso Beattie和Bresnahan(BBB)运动评分量表”评估运动功能,通过机械性异常性疼痛评估疼痛。通过蛋白质印迹分析测量过氧亚硝酸盐水平(作为3-硝基酪氨酸(3-NT)的表达)、钙蛋白酶活性(作为钙蛋白酶底物αII血影蛋白的降解产物)和nNOS活性(作为磷酸化nNOS的表达)。用GSNO治疗可改善运动功能并减轻疼痛。该治疗还降低了过氧亚硝酸盐(3-NT)的水平并降低了钙蛋白酶的活性。过氧亚硝酸盐水平的降低是由于GSNO介导的对神经元型一氧化氮合酶(nNOS)异常活性的抑制。
数据表明,较高水平的3-NT以及nNOS和钙蛋白酶的异常活性与SCI病理和功能缺陷相关。用GSNO治疗可改善运动功能并在损伤后急性减轻机械性异常性疼痛。由于GSNO显示出改善实验性SCI的潜力,我们讨论了GSNO疗法在临床SCI研究中的意义。